Clinical Trial Search

Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants

Primary: Change in Geometric Mean Titre Ratio, A/H1N1 Strain — 3.13; 3.17 Ratio of Day 0 and Day 21-28 titres

Primary: Number and Percentage of Participants With Anti-HBs Seroconversion at Month 7 — 75; 69 Participants

Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units

Primary: Serum Bactericidal Activity Against MenC — 6786; 6278; 2061; 1746 GMTs

Primary: Protective Humoral Immune Response at 1 Month Post First Vaccination. — 12; 12; 12; 11 Participants

Primary: Percentage of Participants With Anti HBs Seroprotection After the 3 Dose Primary Vaccination Series With Either DTaP-IPV-Hep B-PRP~T or PENTAXIM™ + ENGERIX B® Vaccines…

Primary: Percentage of Participants With Seroprotection After Vaccinations With Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Following a Documented Dose of a Commercial…

Primary: Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens — 105; 106; 105; 106 Participants

Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes for Subjects Receiving Synflorix Vaccine Co-administered With Tritanrix-HepB/Hib and Polio Sabin…

Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects

Primary: Count of Participants From Each Arm Who Received Influenza Vaccine — 1; 3; 11; 13 Participants

Primary: Immunogenicity - Geometric Mean Titer Fold Increase From Baseline — 3.5; 4.0; 4.5; 3.4 GMT fold increase

Primary: Change From Baseline in Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus at 28 Days Post Vaccination — 9144 titers

Primary: Number of Participants With Antibody Persistence and Immunogenicity Booster Response to Vaccination With DTaP-Hep B-PRP~T Concomitantly With Oral Polio Vaccine (OPV)…

Primary: Geometric Mean Titer — 3.36; 2.61; 2.46; 2.41 GMT fold increase from baseline

Primary: Primary: 1. Geometric Mean Titers (GMT) at Day 56 — 100.1; 84.7; 68.1 Geometric Mean Titer - Estimate

Primary: Seroprotection Status for Anti-diphteria (Anti-DT) Antibodies — 100; 100; 100; 100 IU/mL

Primary: Number of Participants With Seroprotection After Primary Series Vaccination With DTaP-IPV-Hep B-PRT~T or CombAct Hib™ + Engerix B™ + Oral Polio Vaccine (OPV) — 176; 185…

Primary: Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza…

Primary: SCR (Seroconversion Rate)of IC51 Compared to JE-VAX at Day 56 — 96.4; 93.6 percentage of participants

Primary: Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations — 6.784; 6.493; 18.937; 18.515 IU/mL

Primary: Increase in Geometric Mean Titre Ratio, A/H1N1 Strain — 4.337; 4.702 Ratio of Day 0 and Day 21-28 titres

Primary: Percentage of Subjects With Serum Bactericidal Activity ≥1:5 After Receiving Three Doses of rMenB+OMV NZ Vaccine — 9; 7; 6; 6 Percentages of subjects

Primary: Seropositivity Rate as Determined by Neutralization Test (NT) 28 Days After the Second Vaccination — 100; 97.8 Percentage of participants — p=<0.001

Primary: All-cause Hospitalisations — 637; 633 Events

Primary: Serum Haemagglutination-inhibition (HI) Antibody Titers, Against Each of the Vaccine Influenza Virus Strains. — 21.4; 22.2; 23.3; 18.4 Titer

Primary: Number of Participants With Solicited Injection Site and Systemic Reactions After Injection With Either JE-CV or Hepatitis A Vaccine as First Injection — 15; 13; NA; NA…

Primary: Seroconversion Non-inferiority of 2 Doses f-IPV ID vs 2 Doses IPV IM — 98.1; 95.9; 98.7; 97.9 percentage of seroconversion — p=0.05

Primary: Geometric Mean Peak Plaque Reduction Neutralization Titer (PRNT) After Second Vaccination — 138.0; 55.1; 75.9; 103.5 titers